Effect of dietary supplementation with glucomannan on plasma total cholesterol and low density lipoprotein cholesterol in hypercholesterolemic children

Martino, Francesco De; Martino, Eliana; Morrone, Francesco; Carnevali, Elisabetta; Forcone, R.; Niglio, Tarcisio

doi:10.1016/j.numecd.2004.04.004

Cited by 64 publications

(45 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two of these studies (5,15) reported the results of 2 heterogeneous and mutually distinct populations separately in their articles; therefore, we opted to include each of these analyses in our meta-analysis separately. Eight of the studies were conducted using a parallel study design (4,6,7,(11)(12)(13)(14)16), whereas the other 6 studies used a crossover design. All the crossover studies used a 2-wk washout period, except for the study by Yoshida et al (5), which used a 4-wk washout period.…”

Section: Resultsmentioning

confidence: 99%

Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis

Sood

Baker

Coleman

2008

The American Journal of Clinical Nutrition

163

View full text Add to dashboard Cite

Background: Several clinical trials have investigated the impact of glucomannan on plasma lipids, body weight, fasting blood glucose (FBG), and blood pressure (BP), but have yielded conflicting results and had only modest sample sizes. Objective: The objective was to perform a meta-analysis of randomized controlled trials of glucomannan to better characterize its impact on plasma lipids, FBG, body weight, and BP. Design: A systematic literature search of MEDLINE, EMBASE, CINAHL, Web of Science, the Cochrane Library, and the Natural Medicines Comprehensive Database was conducted from the earliest possible date through November 2007. A random-effects model was used to calculate the weighted mean difference (WMD) and 95% CIs as the difference between the mean for the glucomannan and control groups. Standard methods for assessing statistical heterogeneity and publication bias were used. Results: Fourteen studies (n ҃ 531) met the inclusion criteria. The use of glucomannan significantly lowered total cholesterol [weighted mean difference (WMD): Ҁ19.28 mg/dL; 95% CI: Ҁ24.30, Ҁ14.26], LDL cholesterol (WMD: Ҁ15.99 mg/dL; 95% CI: Ҁ21.31, Ҁ10.67), triglycerides (WMD: Ҁ11.08 mg/dL; 95% CI: Ҁ22.07, Ҁ0.09), body weight (WMD: Ҁ0.79 kg; 95% CI: Ҁ1.53, Ҁ0.05), and FBG (WMD: Ҁ7.44 mg/dL; 95% CI: Ҁ14.16, Ҁ0.72). The use of glucomannan did not appear to significantly alter any other study endpoints. Pediatric patients, patients receiving dietary modification, and patients with impaired glucose metabolism did not benefit from glucomannan to the same degree. Conclusions: Glucomannan appears to beneficially affect total cholesterol, LDL cholesterol, triglycerides, body weight, and FBG, but not HDL cholesterol or BP.

show abstract

Section: Resultsmentioning

confidence: 99%

Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis

Sood

Baker

Coleman

2008

The American Journal of Clinical Nutrition

163

View full text Add to dashboard Cite

show abstract

“…Dennison et al [65] found no additional lowering effect of psyllium fiber on total or LDL-Ch in children who were following a low total fat, low saturated fat, and low cholesterol diet. On the contrary, Martino et al found a significant reduction of TCh after 8 weeks of glucomannan supplementation in association with a hypocholesterolemic diet [66] and Sanchez-Bayle et al obtained a similar result using wheat bran and pectin as a source of fibers [67].…”

Section: Nutraceuticals and Hypercholesterolemiamentioning

confidence: 96%

Nutraceuticals in the Early Infancy

Pignatelli¹,

Basili²

2010

Cardiovascular Therapeutics

View full text Add to dashboard Cite

Atherosclerosis disease and its extent in childhood correlate positively with established risk factors, namely obesity, hypercholesterolemia, diabetes mellitus, and hypertension. The safety and efficacy of some dietary interventions to modulate risk factors in childhood are documented by an increasing body of evidence. The present review analyzes nutritional and nutraceutical current strategies addressed to modify some risk factors of atherosclerosis in childhood. In particular, studies concerning nutrients such as fibers, omega-3-fatty acids, vitamin D, antioxidants, and calcium have been evaluated. An overall analysis suggests that some nutraceuticals might represent an attractive tool to lower the development of atherosclerotic-related cardiovascular complication in children. Nevertheless, at this moment, due to the methodological weakness that characterizes the majority of the analyzed studies, nutrients or supplements should not be considered as a therapeutic tool potentially usable for clinical purpose in children at risk for cardiovascular disease.

show abstract

“…The action of high viscosity glucomannan in decreasing and maintaining the targeted cholesterolemia is also validated by the European Food Safety Authority (EFSA) report and many clinical trials [72,[74][75][76][78][79][80]. Other nutraceuticals as chromium-polynicotinate and policosanol were investigated in the treatment of lipid disorders showing cholesterol-lowering effects [79][80][81].…”

Section: Nutraceuticals and Hypercholesterolemiamentioning

confidence: 98%

“…This fiber may decrease serum levels of total cholesterol and LDL-cholesterol without changes in HDL-cholesterol. Previous studies demonstrated these positive effects in adults [74,75] and in children [76,77]. A meta-analysis of 14 studies (N = 531 subjects) showed that glucomannan seems to have beneficial effects on total cholesterol, LDL-cholesterol, triglycerides, body weight, fasting blood glucose but not on HDL-cholesterol or blood pressure [78].…”

Section: Nutraceuticals and Hypercholesterolemiamentioning

confidence: 98%

Dietary Fibers and Nutraceuticals for Primary Cardiovascular Prevention in Children and Adolescents: A Critical Review

Martino¹,

Puddu²,

Pannarale³

et al. 2013

FNS

Self Cite

View full text Add to dashboard Cite

The roles of dietary fibers and nutraceuticals for primary prevention of cardiovascular disease from childhood are reviewed. Nutrition as an epigenetic modifier and the roles of endothelium, risk factors, epidemiological evidence and Mediterranean diet are critically analysed. Overfeeding in childhood can lead to the development of obesity and/or atherosclerosis in adult life. In particular, a high intake of nutrients affects the in utero programming with the adverse consequences of insulin resistance an endothelial dysfunction that lead to early atherosclerosis. Dietary fibers have important health benefits in childhood and research suggests that they may prevent obesity and lower blood cholesterol levels with a favourable impact on the risk of future cardiovascular disease incidence. However, it is for further studies to assess whether also in Southern European Countries, practicing Mediterranean diet as a normal habit, dietary fibers may contribute to modify the relatively low proportion of hyperlipemia observed in our population.

show abstract

Effect of dietary supplementation with glucomannan on plasma total cholesterol and low density lipoprotein cholesterol in hypercholesterolemic children

Cited by 64 publications

References 24 publications

Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis

Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis

Nutraceuticals in the Early Infancy

Dietary Fibers and Nutraceuticals for Primary Cardiovascular Prevention in Children and Adolescents: A Critical Review

Contact Info

Product

Resources

About